普洛药业(000739.SZ)：头孢地尼干混悬剂获得药品注册证书

Core Viewpoint - Prolo Pharmaceutical (000739.SZ) announced that its wholly-owned subsidiary, Zhejiang Prolo Jutai Pharmaceutical Co., Ltd., received a drug registration certificate from the National Medical Products Administration for Cefdinir Dry Suspension (1.5g; 3.0g) [1] Group 1 - Cefdinir Dry Suspension is classified as a third-generation oral cephalosporin antibiotic [1] - The drug is indicated for the treatment of mild to moderate infections in pediatric patients caused by specified strains of sensitive microorganisms under certain conditions [1] Group 2 - The specific infections targeted include acute bacterial otitis media caused by Haemophilus influenzae (including beta-lactamase producing strains), Streptococcus pneumoniae (only penicillin-sensitive strains), and Moraxella catarrhalis (including beta-lactamase producing strains) [1] - Additionally, it is effective for pharyngitis/tonsillitis caused by Streptococcus pyogenes and uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including beta-lactamase producing strains) and Streptococcus pyogenes [1]